Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,713.50GBp
10 Dec 2018
Change (% chg)

9.00 (+0.53%)
Prev Close
1,704.50
Open
1,683.00
Day's High
1,730.00
Day's Low
1,680.00
Volume
404,777
Avg. Vol
591,907
52-wk High
2,089.00
52-wk Low
814.20

Latest Key Developments (Source: Significant Developments)

Hikma Announces Agreement With Vectura
Thursday, 8 Nov 2018 02:01am EST 

Nov 8 (Reuters) - Hikma Pharmaceuticals Plc ::HIKMA ANNOUNCES AGREEMENT WITH VECTURA.UPON SIGNING, HIKMA WILL MAKE AN UPFRONT PAYMENT OF $15 MILLION TO VECTURA.VECTURA WILL BE RESPONSIBLE FOR, AND FUND, INITIAL DEVICE AND FORMULATION DEVELOPMENT.DEAL FOR GLOBAL DEVELOPMENT AND COMMERCIALISATION OF GENERIC VERSIONS OF GSK'S ELLIPTA PORTFOLIO.UPON TRANSFER OF 1ST PRODUCT TO CO'S MANUFACTURING FACILITY, WILL MAKE $5 MILLION MILESTONE PAYMENT TO VECTURA.THEREAFTER, HIKMA WILL MAKE MILESTONE PAYMENTS OF UP TO $75 MILLION AT VARIOUS STAGES OF DEVELOPMENT.VECTURA WILL CONTRIBUTE UP TO $70 MILLION TOWARDS HIKMA'S DEVELOPMENT ACTIVITIES FOR PORTFOLIO.HIKMA PHARMACEUTICALS - VECTURA'S CONTRIBUTION TO BE MADE THROUGH REDUCED PROFIT SHARE MECHANISM FOLLOWING COMMERCIAL LAUNCH OF FIRST PRODUCT.  Full Article

Hikma Pharmaceuticals Raises Guidance For Injectables, Generics Businesses For Full Year
Wednesday, 15 Aug 2018 02:00am EDT 

Aug 15 (Reuters) - Hikma Pharmaceuticals PLC ::H1 OPERATING PROFIT 174 MILLION USD VERSUS 113 MILLION USD YEAR AGO.H1 REVENUE 989 MILLION USD VERSUS 895 MILLION USD YEAR AGO.INTERIM DIVIDEND 0.12 USDPER SHARE.GUIDANCE RAISED FOR INJECTABLES AND GENERICS BUSINESSES AND REITERATED FOR BRANDED BUSINESS.RAISE GUIDANCE FOR BOTH OUR INJECTABLES AND GENERICS BUSINESSES FOR FULL YEAR.NOW EXPECT FULL YEAR INJECTABLES REVENUE TO BE IN RANGE OF $775 MILLION TO $825 MILLION.EXPECT GENERICS FULL YEAR REVENUE TO BE IN RANGE OF $600 MILLION TO $650 MILLION.EXPECT BRANDED REVENUES TO BE HIGHER IN SECOND HALF OF YEAR.EXPECT FULL YEAR BRANDED REVENUE GROWTH IN CONSTANT CURRENCY TO BE IN MID-SINGLE DIGITS.DON'T EXPECT SAME DEMAND FOR SOME OF OUR INJECTABLE PRODUCTS TO CONTINUE INTO 2019.NOT CLEAR HOW LONG INJECTABLE OPIOIDS SHORTAGES WILL PERSIST; DON'T EXPECT TO SEE SAME LEVEL OF DEMAND CONTINUE INTO 2019.MENA INJECTABLES REVENUE WAS $51 MILLION IN H1 2018, UP 46%.IN H1 2018, GLOBAL INJECTABLES REVENUE INCREASED BY 14% TO $414 MILLION.CONTINUE TO EXPECT GROUP CAPITAL EXPENDITURE IN RANGE OF $120 MILLION TO $140 MILLION IN 2018.  Full Article

Acorda Updates On Litigation With Mylan, Teva, West-Ward Pharma & Hikma
Friday, 3 Aug 2018 06:05am EDT 

Aug 3 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS - UPDATES ON LITIGATION WITH MYLAN, TEVA, WEST-WARD PHARMACEUTICALS INTERNATIONAL & HIKMA PHARMACEUTICALS USA.ACORDA THERAPEUTICS - TERMS OF SETTLEMENT AGREEMENT WITH MYLAN AND INTERIM AGREEMENTS WITH TEVA AND HIKMA ARE OTHERWISE CONFIDENTIAL.ACORDA THERAPEUTICS - MYLAN WILL BE PERMITTED TO MARKET ITS GENERIC VERSION OF AMPYRA IN U.S. SOMETIME IN 2025/EARLIER AS PER A CONDITIONED SETTLEMENT WITH CO.ACORDA THERAPEUTICS - SIGNED INTERIM AGREEMENT WITH TEVA CONCERNING PATENT LITIGATION RELATING TO AMPYRA THAT ADDRESSES PERIOD OF TIME UNTIL AUG 31.ACORDA THERAPEUTICS SAYS ALSO SIGNED INTERIM AGREEMENT WITH HIKMA CONCERNING THEIR PATENT LITIGATION RELATING TO AMPYRA - SEC FILING.  Full Article

Hikma Pharmaceuticals Says U.S. Business Releases Hydromorphone To Hospital Customers
Wednesday, 18 Jul 2018 07:00am EDT 

July 18 (Reuters) - Hikma Pharmaceuticals PLC ::CO'S US BUSINESS RELEASING "SIGNIFICANT QUANTITIES" OF HYDROMORPHONE TO US HOSPITAL CUSTOMERS TO HELP WITH SHORTAGE OF INJECTABLE OPIOIDS.RELEASED MORE THAN 5 MILLION HYDROMORPHONE 2ML VIALS TO US HOSPITALS IN JUNE, EXPECTS TO RELEASE ANOTHER THREE MILLION VIALS IN JULY.  Full Article

Hikma Enters Licensing Partnership With Perrigo
Monday, 9 Jul 2018 04:00am EDT 

July 9 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA ENTERS LICENSING PARTNERSHIP WITH PERRIGO.SIGNED LICENSING AND DISTRIBUTION AGREEMENT WITH OMEGA PHARMA TRADING NV.HIKMA HAS EXCLUSIVE RIGHT TO LICENSE AND DISTRIBUTE MORE THAN 30 CONSUMER HEALTHCARE PRODUCTS IN ALL ITS MENA MARKETS.IN ADDITION, HIKMA HAS RIGHT OF FIRST REFUSAL TO FULL RANGE OF PERRIGO'S OTC MEDICINES IN MENA REGION.  Full Article

Hikma Pharmaceuticals Reiterate Ourtlook For Generics 2018 Revenues In $550-$600 mln Range
Friday, 18 May 2018 02:00am EDT 

May 18 (Reuters) - Hikma Pharmaceuticals PLC ::REITERATE EXPECTATIONS FOR GENERICS REVENUES IN 2018 IN RANGE OF $550 MILLION TO $600 MILLION.FOR FULL YEAR, CONTINUE TO EXPECT INJECTABLES REVENUE TO BE IN RANGE OF $750 MILLION TO $800 MILLION.CONTINUE TO EXPECT COMPETITION TO ACCELERATE OVER COURSE OF YEAR IN INJECTABLES.REITERATE GUIDANCE FOR FULL YEAR.FOR FULL YEAR, WE CONTINUE TO EXPECT INJECTABLES REVENUE TO BE IN RANGE OF $750 MILLION TO $800 MILLION.FOR FULL YEAR CONTINUE TO EXPECT CORE INJECTABLES OPERATING MARGIN TO RETURN TO MORE NORMALISED LEVELS IN LOW TO MID 30S.CONTINUE TO FOCUS ON OPTIMISING COST BASE, REMAIN ON TRACK TO COMPLETE CONSOLIDATION OF MANUFACTURING AND DISTRIBUTION FACILITIES IN H2.IN 2017, EXPECT STRONGER SECOND HALF, REFLECTING USUAL SEASONALITY OF THIS BUSINESS IN BRANDED.DURING QUARTER INITIATED REPEAT CLINICAL ENDPOINT STUDY FOR GENERIC ADVAIR DISKUS.CONTINUE TO EXPECT BRANDED REVENUE GROWTH FOR FULL YEAR TO BE IN MID-SINGLE DIGITS IN CONSTANT CURRENCY.STUDY FOR GENERIC ADVAIR STUDY IS PROCEEDING AS PLANNED, EXPECT TO SUBMIT RESPONSE TO FDA WITH NEW CLINICAL DATA AS EARLY AS POSSIBLE IN 2019.AS IN 2017, WE EXPECT A STRONGER SECOND HALF IN BRANDED.CONTINUE TO EXPECT BRANDED REVENUE GROWTH FOR FULL YEAR TO BE IN MID-SINGLE DIGITS.  Full Article

Hikma Signs Licensing Agreement With Rovi For Enoxaparin Biosimilar
Tuesday, 24 Apr 2018 04:00am EDT 

April 24 (Reuters) - Hikma Pharmaceuticals Plc ::SAYS EXPANDS LICENSING AGREEMENT WITH ROVI.SIGNED A LICENSING AGREEMENT WITH LABORATORIOS FARMACEÚTICOS ROVI SA FOR THEIR ENOXAPARIN BIOSIMILAR.UNDER TERMS OF AGREEMENT, HIKMA HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET ENOXAPARIN ACROSS ITS MENA MARKETS.  Full Article

Vanda Pharmaceuticals Wins Appeal Case On Fanapt
Friday, 13 Apr 2018 12:00pm EDT 

April 13 (Reuters) - Vanda Pharmaceuticals Inc ::VANDA WINS APPEAL CASE ON FANAPT®.U.S. FEDERAL COURT AFFIRMED U.S. COURT'S DECISION THAT WEST WARD PHARMACEUTICALS INFRINGED CO'S U.S. '610 PATENT FOR FANAPT.'610 PATENT IS SET TO EXPIRE NOVEMBER 2, 2027.  Full Article

Hikma Pharmaceuticals FY Revenue 1.936 Billion USD
Wednesday, 14 Mar 2018 03:00am EDT 

March 14 (Reuters) - Hikma Pharmaceuticals Plc ::FY OPERATING LOSS -747 MILLION USD VERSUS 302 MILLION USD PROFIT YEAR AGO.FY REVENUE 1.936 BILLION USD.FINAL DIVIDEND 0.23 USD PER SHARE.TOTAL DIVIDEND 0.34 USD PER SHARE.FY CORE EBITDA $‍468​ MILLION VERSUS $493 MILLION AS REPORTED YEAR-AGO.SAYS GENERICS REVENUE WAS $615 MILLION IN 2017, UP FROM $604 MILLION IN 2016.‍EXPECT INJECTABLES REVENUE IN 2018 WILL BE IN RANGE OF $750 MILLION TO $800 MILLION​.‍IDENTIFYING FURTHER COST SAVINGS FOR GENERICS BUSINESS​.SAYS FY CORE OPERATING PROFIT OF $386 MILLION, DOWN 8% AND DOWN 4% IN CONSTANT CURRENCY.‍EXPECT CORE INJECTABLES OPERATING MARGIN TO RETURN TO MORE NORMALISED LEVELS IN LOW TO MID 30'S IN 2018​.‍EXPECT GENERICS REVENUES IN 2018 WILL BE IN RANGE OF $550 MILLION TO $600 MILLION​.‍2018 CORE GENERICS OPERATING MARGIN IN LOW SINGLE DIGITS BEFORE ADJUSTING FOR LOWER DEPRECIATION RELATED TO 2017 IMPAIRMENT.‍EXPECT 2018 BRANDED REVENUE GROWTH IN CONSTANT CURRENCY IN MID-SINGLE DIGITS​.  Full Article

Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​
Thursday, 9 Nov 2017 02:00am EST 

Nov 9 (Reuters) - HIKMA PHARMACEUTICALS PLC ::‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​.FOR FULL YEAR ‍CONTINUE TO EXPECT GLOBAL INJECTABLES REVENUE TO BE AROUND $775 MILLION, WITH A VERY STRONG CORE OPERATING MARGIN OF AROUND 39%​.‍EXPECT GENERICS REVENUE TO BE AROUND $600 MILLION FOR FULL YEAR AND CORE OPERATING MARGIN TO BE IN LOW SINGLE-DIGITS​.‍REITERATING EXPECTATION FOR BRANDED REVENUE GROWTH IN MID-SINGLE DIGITS IN CONSTANT CURRENCY IN 2017​.  Full Article

Photo

Hikma raising injectable opioids output to help ease shortage at U.S. hospitals

LONDON London-listed pharmaceutical group Hikma said on Wednesday it was increasing its supply of hydromorphone to U.S. hospitals to help ease a shortage of injectable opioids used to treat patients.